![](https://investorshub.advfn.com/uicon/189332.png?cb=1465554763)
Monday, November 17, 2014 12:20:12 PM
1) NNVC doesn't have a drug of any kind in Clinical testing as yet, and thus has no track record and no real credibility in the medical/pharma community,..... YET.
2) NNVC doesn't have an Ebola treatment in hand that could (again yet) be tested on a person in either a Clinical or Pre-Clinical situation and so has no real credibility as any anti-Ebola company,..... YET.
3) As a developmental-stage company that has historically NOT kept on a rigorous timeline and historically (to be kind) has been optimistic about when things would get done,.... the company has no track record and no real credibility in the biopharma community,..... YET. In particular - the lack of ready-to-roll production facilities hurts us a bit on this credibility front.
Get an Ebolacide2 through it's paces at USAMRIID that shows a realistic chance of being a useful treatment AND get the Shelton plant online and mass-producing 'Cides,.... that'll get the company on everybody's map.
That's the reality that NNVC has to work to overcome before 'we' are taken seriously IMO.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM